WO2003006017A3 - Use of certain castanospermine esters in the treatment of influenza virus infections - Google Patents

Use of certain castanospermine esters in the treatment of influenza virus infections Download PDF

Info

Publication number
WO2003006017A3
WO2003006017A3 PCT/EP2002/007632 EP0207632W WO03006017A3 WO 2003006017 A3 WO2003006017 A3 WO 2003006017A3 EP 0207632 W EP0207632 W EP 0207632W WO 03006017 A3 WO03006017 A3 WO 03006017A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
influenza virus
virus infections
esters
castanospermine esters
Prior art date
Application number
PCT/EP2002/007632
Other languages
French (fr)
Other versions
WO2003006017A2 (en
Inventor
Albert Stanley Tyms
Original Assignee
Virogen Ltd
Albert Stanley Tyms
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd, Albert Stanley Tyms filed Critical Virogen Ltd
Priority to AU2002325312A priority Critical patent/AU2002325312A1/en
Publication of WO2003006017A2 publication Critical patent/WO2003006017A2/en
Publication of WO2003006017A3 publication Critical patent/WO2003006017A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of certain castanospermine esters in the treatment of influenza virus infection and compositions containing said esters in combination with adjunctive therapeutic agents.
PCT/EP2002/007632 2001-07-09 2002-07-08 Use of certain castanospermine esters in the treatment of influenza virus infections WO2003006017A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002325312A AU2002325312A1 (en) 2001-07-09 2002-07-08 Use of certain castanospermine esters in the treatment of influenza virus infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0116643.8 2001-07-09
GBGB0116643.8A GB0116643D0 (en) 2001-07-09 2001-07-09 Antiviral compounds

Publications (2)

Publication Number Publication Date
WO2003006017A2 WO2003006017A2 (en) 2003-01-23
WO2003006017A3 true WO2003006017A3 (en) 2003-08-28

Family

ID=9918105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007632 WO2003006017A2 (en) 2001-07-09 2002-07-08 Use of certain castanospermine esters in the treatment of influenza virus infections

Country Status (3)

Country Link
AU (1) AU2002325312A1 (en)
GB (1) GB0116643D0 (en)
WO (1) WO2003006017A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
EP3934688A4 (en) * 2019-03-08 2022-12-21 University of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
WO2002089780A2 (en) * 2001-05-03 2002-11-14 Virogen Ltd Antiviral compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
WO2002089780A2 (en) * 2001-05-03 2002-11-14 Virogen Ltd Antiviral compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAMMOND C ET AL: "ROLE OF N-LINKED OLIGOSACCHARIDE RECOGNITION, GLUCOSE TRIMMING, AND CALNEXIN IN GLYCOPROTEIN FOLDING AND QUALITY CONTROL", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, no. 3, 1 February 1994 (1994-02-01), pages 913 - 917, XP002035740, ISSN: 0027-8424 *
MEHTA A ET AL: "alpha-Glucosidase inhibitors as potential broad based anti-viral agents", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 430, no. 1-2, 23 June 1998 (1998-06-23), pages 17 - 22, XP004259130, ISSN: 0014-5793 *
MIST (MANAGEMENT OF INFLUENZA IN THE SOUTHERN HEMISPHERE TRIALISTS) STUDY GROUP T: "Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections", LANCET, XX, XX, vol. 352, no. 9144, 12 December 1998 (1998-12-12), pages 1877 - 1881, XP004265783, ISSN: 0140-6736 *
NICHOL K L: "Complications of influenza and benefits of vaccination", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, 30 July 1999 (1999-07-30), pages S47 - S52, XP004173584, ISSN: 0264-410X *
NICHOLSON K G ET AL: "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial", LANCET, XX, XX, vol. 355, no. 9218, 27 May 2000 (2000-05-27), pages 1845 - 1850, XP004263555, ISSN: 0140-6736 *
SAITO TAKEHIKO ET AL: "Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins.", JOURNAL OF VETERINARY MEDICAL SCIENCE, vol. 62, no. 6, June 2000 (2000-06-01), pages 575 - 581, XP001135294, ISSN: 0916-7250 *
TAYLOR D L ET AL: "Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase.", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 6, no. 3, 1995, pages 143 - 152, XP001119625, ISSN: 0956-3202 *

Also Published As

Publication number Publication date
GB0116643D0 (en) 2001-08-29
WO2003006017A2 (en) 2003-01-23
AU2002325312A1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
AU2002360517A1 (en) Respiratory infection prevention and treatment with terpene-containing compositions
CY1110437T1 (en) USE OF KASTANOSPERMIN PRODUCTS FOR THE TREATMENT OF USITIS C
EP1689348A4 (en) Oligosaccharide compositions and use thereof in the treatment of infection
CL2004001174A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING: 1- (4-FLUOROPHENYL) -3 (R) - [3- (4-FLUOROPHENYL) -3 (S) -HYDROXIPROPIL] -4 (S) - (4-HYDROXIFENYL) -2-ACETIDINONE ( EZETIMIBA) AND EXCIPIENTS; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, DAY
SE0102315D0 (en) Compounds
WO2006034001A3 (en) Methods of treating hiv infection
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
AU2002347152A1 (en) Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
WO2003006017A3 (en) Use of certain castanospermine esters in the treatment of influenza virus infections
WO2004054603A3 (en) Use of beta-defensins for treating hiv infections
AU2002332613A1 (en) Compositions and therapeutic methods for viral infection
AU2002323443A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2002351176A1 (en) Peptides and use thereof in therapeutic agents against hiv infection
AU2003255866A8 (en) Gp41 epitope and uses thereof for the treatment of hiv infections
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
ES2195861T3 (en) USE OF (IR, 4S) -4- (6-AMINO-9H-PURIN-9-IL) -2-CICLOPENTEN-1-METHANOL IN VHB.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP